Company: ATRA
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0000950170-25-059322
Chunk: 60

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 60
---
 of approximately one year of service, and thereafter, an additional approximately 1/16th of the total number of shares underlying the RSUs vest on specific dates that approximately quarterly vesting, subject to continuous service.

Represents options issued under the 2014 Plan. 25% of the shares subject to the options vest upon completion of one year of service, and thereafter, an additional 1/48th of the total number of shares underlying the options vest each month, subject to continuous service.

Represents RSUs issued under the 2014 Plan. 1/8th of the total number of shares under the RSUs vest on specific dates that approximately quarterly vesting from the grant date, subject to continuous service.

Represents RSUs issued under the Atara Biotherapeutics, Inc. 2024 Equity Incentive Plan (the “2024 Plan”). 1/12th of the total number of shares under the RSUs vest on specific dates that approximately quarterly vesting from the grant date, subject to continuous service.

Represents RSUs issued under the 2014 Plan. 1/4th of the total number of shares under the RSUs vest annually measured from the grant date, subject to continuous service.

Employment Contracts and Change in Control Arrangements

Pascal Touchon, D.V.M.

We entered into an executive employment agreement with Dr. Touchon in May 2019 (the “Touchon Employment Agreement”) in connection with him joining the Company as our President and Chief Executive Officer in June 2019. Dr. Touchon resigned as our President and Chief Executive Office and was appointed chair of the Board, effective September 9, 2024. In connection with his resignation, we entered into a transition, separation and consulting agreement with Dr. Touchon (“Transition Agreement”) which superseded and replaced the Touchon Employment Agreement. Pursuant to the Transition Agreement, Dr. Touchon received the following post-termination benefits: (i) a pro-rated portion of his 2024 target cash bonus amount based on the number of days of his employment during the 2024 calendar year; (ii) retainment of Dr. Touchon by us for consulting services, for a period of 12 months, which the Board may elect to extend an additional six months, with consulting fees of $23,000 per month; (iii) acceleration of certain equity awards upon a change of control of the Company; and (iv) insurance coverage under COBRA for a period of